Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters











Database
Language
Publication year range
1.
Sex Transm Dis ; 49(4): 313-317, 2022 04 01.
Article in English | MEDLINE | ID: mdl-35312669

ABSTRACT

BACKGROUND: The National Network of Sexually Transmitted Disease Clinical Prevention Training Centers (NNPTC) trains clinical providers to diagnose and treat sexually transmitted infections (STIs) in the United States. The purpose of this study was to examine the demographics of clinical providers and to correlate the number of training episodes with STI rates at the county level. METHODS: Registration data were collected between April 1, 2015, and March 31, 2020, in a custom Learning Management System from clinical providers taking NNPTC training. Using the 2018 STI surveillance data, counties were divided into quartiles based on reportable STI case rates and the number of county-level training events was compared per quartile. Univariate and multivariate analyses were conducted in IBM SPSS Statistics 23 (Armonk, NY) and SAS Enterprise Guide 7.1 (Cary, NC). RESULTS: From 2015 to 2020, the NNPTC trained 21,327 individuals, predominantly in the nursing professions and working in a public health environment. In multivariate analysis, the number of training events was significantly associated with higher STI rates at the county level (P < 0.0001) and the state where a prevention training center is located (P < 0001). CONCLUSIONS: The analysis suggests that NNPTC trainings are reaching the clinical providers working in geographic areas with higher STI rates.


Subject(s)
Sexually Transmitted Diseases , Humans , Public Health , Sexually Transmitted Diseases/diagnosis , Sexually Transmitted Diseases/epidemiology , Sexually Transmitted Diseases/prevention & control , United States/epidemiology
2.
Sex Transm Dis ; 48(12): e190-e191, 2021 12 01.
Article in English | MEDLINE | ID: mdl-34110744

ABSTRACT

ABSTRACT: Chlamydia, gonorrhea, and primary/secondary syphilis rates in 2018 were significantly higher in counties located in states without Medicaid expansion compared with those with Medicaid expansion. For sexually transmitted infections combined, 59.9% of counties without Medicaid expansion were in the highest 2 sexually transmitted infection rate quartiles compared with 42.2% of counties with Medicaid expansion (P < 0.0001).


Subject(s)
Chlamydia Infections , Gonorrhea , Sexually Transmitted Diseases , Syphilis , Chlamydia Infections/epidemiology , Gonorrhea/epidemiology , Humans , Medicaid , Sexually Transmitted Diseases/epidemiology , Syphilis/epidemiology , United States/epidemiology
3.
Sex Transm Dis ; 48(1): e1-e4, 2021 01.
Article in English | MEDLINE | ID: mdl-32649580

ABSTRACT

The national Sexually Transmitted Diseases (STD) Clinical Consultation Network receives requests regarding complex STD cases. A total of 927 requests from Western states, 2017 to 2019, were analyzed for STD of inquiry and syphilis-specific subtopics. Syphilis requests accounted for most queries, and the number and proportion of syphilis-related requests increased significantly over time.


Subject(s)
Sexually Transmitted Diseases , Syphilis , Humans , Referral and Consultation , Sexually Transmitted Diseases/diagnosis , Sexually Transmitted Diseases/epidemiology , Syphilis/diagnosis , Syphilis/epidemiology
4.
JAMA ; 300(8): 945-51, 2008 Aug 27.
Article in English | MEDLINE | ID: mdl-18728268

ABSTRACT

The Centers for Disease Control and Prevention (CDC) has recommended human immunodeficiency virus (HIV) testing for all persons aged 13 to 64 years in all health care settings. Signed consent would not be required and counseling with referral would be managed as it is for other serious conditions. The goal of the recommendations is to promote earlier entry into care to reduce unnecessary mortality and facilitate prevention by behavioral changes that accompany knowledge of serostatus. Concerns about the change include laws in some states that mandate signed consent and counseling, a perception that counseling is an effective prevention strategy, variability in payment coverage for the test, concerns about the stigma and discrimination that may accompany the HIV diagnosis, and the possibility that other testing policies would be more effective. Eleven of 16 states have changed legislation to reduce barriers to testing, 35 of 74 national professional societies have endorsed the new recommendations, and multiple demonstration projects have shown feasibility. Metrics to evaluate the health outcomes of the CDC's recommendations for HIV testing have been defined, but the data necessary to determine the effects on early entry into care, the actual reduction in disease incidence, and the unanticipated consequences are not yet available.


Subject(s)
AIDS Serodiagnosis , HIV Infections/prevention & control , AIDS Serodiagnosis/economics , AIDS Serodiagnosis/standards , AIDS Serodiagnosis/statistics & numerical data , AIDS Serodiagnosis/trends , Adolescent , Adult , Centers for Disease Control and Prevention, U.S. , Cost-Benefit Analysis , Female , HIV Infections/epidemiology , Health Planning Guidelines , Humans , Informed Consent , Life Tables , Male , Mass Screening/standards , Mass Screening/trends , Middle Aged , United States/epidemiology
5.
Am J Physiol Renal Physiol ; 289(4): F760-7, 2005 Oct.
Article in English | MEDLINE | ID: mdl-15942047

ABSTRACT

The pathways responsible for the rapid and sustained increases in [Ca(2+)](i) following activation of ANG II receptors (AT(1)) in renal vascular smooth muscle cells were evaluated using fluorescence microscopy. Resting intracellular calcium concentration [Ca(2+)](i) averaged 75 +/- 9 nM. The response to ANG II (100 nM) was characterized by a rapid initial increase of [Ca(2+)](i) by 74 +/- 6 nM (n = 35) followed by a decrease to a sustained level of 12 +/- 2 nM above baseline. The average time from peak to 50% reduction from the peak value (50% time point) was 32 +/- 4 s. AT(1) receptor blockade with 1 microM candesartan (n = 5) prevented the responses to ANG II. In nominally calcium-free conditions (n = 8), the peak increase in [Ca(2+)](i) averaged 42 +/- 7 nM but the sustained phase was absent and the 50% time point was reduced to 11 +/- 4 s. L-type calcium channel blockade with diltiazem reduced the peak [Ca(2+)](i) to 24 +/- 8 nM and the sustained level to 4 +/- 2 nM (n = 10). In cells preincubated in low Cl(-) (3.0 mM), the peak response to ANG II was suppressed as was the sustained response. Blockade of chloride channels with DIDS eliminated both the peak and sustained responses (n = 11); chloride channel blockade with DPC (n = 17) suppressed the peak increase in [Ca(2+)](i) to 18 +/- 5 and also prevented the sustained response. IP3 receptor blockade by 10 microM TMB-8 (n = 6) reduced the peak to 22 +/- 8 and prevented the sustained response. Exposure to 10 microM TMB-8 in the presence of Ca(2+)-free medium prevented the ANG II response (n = 9). In the presence of 100 microM DPC and 10 microM TMB-8 (n = 7), the ANG II response was also prevented. Thus the rapid initial increase in [Ca(2+)](i) is due not only to release from intracellular stores, but also to Ca(2+) influx from the extracellular fluid. Although Ca(2+) entry via L-type calcium channels is responsible for the major portion of the sustained response, other entry pathways participate. The finding that chloride channel blockers markedly attenuate both rapid and sustained responses indicates that chloride channel activation contributes to, rather than being the consequence of, the initial rapid response.


Subject(s)
Calcium Channels/metabolism , Chloride Channels/metabolism , Muscle, Smooth, Vascular/metabolism , Receptor, Angiotensin, Type 1/physiology , 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid/pharmacology , Angiotensin II/pharmacology , Animals , Benzimidazoles/pharmacology , Biphenyl Compounds , Calcium/metabolism , Calcium Channel Blockers/pharmacology , Calibration , Capillaries/cytology , Capillaries/drug effects , Capillaries/metabolism , Cell Separation , Diltiazem/pharmacology , Gallic Acid/analogs & derivatives , Gallic Acid/pharmacology , In Vitro Techniques , Inositol 1,4,5-Trisphosphate/pharmacology , Male , Muscle, Smooth, Vascular/cytology , Muscle, Smooth, Vascular/drug effects , Potassium Chloride/pharmacology , Rats , Rats, Sprague-Dawley , Tetrazoles/pharmacology , Vasoconstrictor Agents/pharmacology , ortho-Aminobenzoates/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL